Acceleron Pharma (XLRN)
ChartMill assigns a Buy % Consensus number of 73% to XLRN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 182.68. This target is 2.2% above the current price.
XLRN was analyzed by 17 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about XLRN.
In the last month the buy percentage fell by 5 points. So the trust of analysts is decreasing.
XLRN was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2021-10-07 | Jefferies | Initiate | Hold |
| 2021-10-04 | Raymond James | Downgrade | Strong Buy -> Market Perform |
| 2021-10-01 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2021-10-01 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2021-10-01 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-09-30 | SVB Leerink | Maintains | Market Perform |
| 2021-09-30 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2021-09-30 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-09-27 | RBC Capital | Maintains | Sector Perform |
| 2021-03-23 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2021-03-12 | Wolfe Research | Initiate | Outperform |
| 2021-03-01 | Citigroup | Maintains | Buy |
| 2021-02-26 | SVB Leerink | Maintains | Outperform |
| 2021-02-26 | Morgan Stanley | Maintains | Overweight |
| 2021-02-26 | Piper Sandler | Maintains | Overweight |